In animal models, NU-9 was found to show promise in treating Alzheimer's by reducing toxic protein buildup and brain inflammation.

Experimental drug NU-9 -- a small molecule compound approved by the U.S. Food and Drug Administration (FDA) for clinical trials for the treatment of amyotrophic lateral sclerosis (ALS) -- improves ...

Experimental drug NU-9—a small molecule compound approved by the U.S. Food and Drug Administration (FDA) for clinical trials ...

Damage to the genetic material of mitochondria—the mitochondrial DNA or mtDNA for short—can lead to diseases such as ...

Damage to the genetic material of mitochondria – the mitochondrial DNA or mtDNA for short – can lead to diseases such as Parkinson's, Alzheimer's, amyotrophic lateral sclerosis (ALS), cardiovascular ...

Damage to the mitochondria, the 'power plants' of the cells, contributes to many diseases. Researchers now describe how cells with defective mitochondria activate a special recycling system to ...

Edaravone may exert its neuroprotective effects in ALS by also correcting the abnormal localization of TDP-43, a key ...

Damage to the genetic material of mitochondria – the mitochondrial DNA or mtDNA for short – can lead to diseases such as Parkinson's, Alzheimer's ...

A research group led by Gian Gaetano Tartaglia, Principal Investigator at the Italian Institute of Technology (IIT), ...

Infectious Diseases and Tropical Medicine Research Center, Research Institute of Cellular and Molecular Sciences in Infectious Diseases, Zahedan University of Medical Sciences, Zahedan 98167-43463, ...